<DOC>
	<DOC>NCT00657137</DOC>
	<brief_summary>This study will compare the anti-tumor efficacy of apricoxib and lapatinib/capecitabine with placebo and lapatinib/capecitabine as measured by time to disease progression and evaluate urinary PGE-M measurements or baseline COX-2 expression in tumor tissue by IHC as a surrogate selection criterion for patients who will benefit from future treatment with apricoxib.</brief_summary>
	<brief_title>APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Females with pathologically determined locally advanced or metastatic human epidermal growth factor receptor 2 positive (HER2/neu+) breast cancer Have progressed after treatment with chemotherapy including a taxane and trastuzumab Must have measurable disease by RECIST ECOG PS of 0,1, or 2 MUGA scan or echocardiogram results show left ventricular ejection fraction greater than or equal to 50% Radiation therapy within 2 weeks, chemotherapy within 3 weeks, or noncytoxic investigational agents within 4 weeks of initiating study treatment Evidence of New York Heart Association class III or greater cardiac disease History of MI, stroke, ventricular arrhythmia, or symptomatic conduction abnormality History of congenital QT prolongation Concurrent severe or uncontrolled medical disease Symptomatic central nervous system metastases Pregnant or nursing women Hypersensitivity or intolerance to apricoxib, lapatinib, capecitabine, 5FU, sulfonamides, aspirin, or NSAIDs Severe renal insufficiency History of upper GI bleeding, ulceration, or perforation Concurrent use of potent CYP3A4 inhibitors and CYP3A4 inducers Prior treatment with capecitabine Patients on antiarrhythmic treatment Prior lapatinib therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>HER2/neu positive</keyword>
	<keyword>locally advanced or metastatic</keyword>
</DOC>